Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.’s FY2018 Earnings (CEMI)
Chembio Diagnostics, Inc. (NASDAQ:CEMI) – Stock analysts at Zacks Investment Research increased their FY2018 EPS estimates for Chembio Diagnostics in a note issued to investors on Wednesday. Zacks Investment Research analyst B. Marckx now forecasts that the company will post earnings per share of ($0.23) for the year, up from their previous estimate of ($0.27). Zacks Investment Research also issued estimates for Chembio Diagnostics’ FY2019 earnings at ($0.11) EPS.
Shares of Chembio Diagnostics (NASDAQ:CEMI) traded down $0.13 on Monday, hitting $7.15. 10,700 shares of the stock traded hands, compared to its average volume of 21,171. Chembio Diagnostics has a 52 week low of $5.05 and a 52 week high of $7.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 2.19.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/11/zacks-investment-research-weighs-in-on-chembio-diagnostics-inc-s-fy2018-earnings-cemi.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.